Here are five things to know.
- While industry sources did not identify the entity interested in purchasing the business, they did estimate the deal could be worth as much as $2.5 billion, reported WSJ.
- The Canadian drugmaker acquired the eye-surgery business in 2013 through the acquisition of Bausch & Lomb.
- The eye unit sells lasers, tools and other equipment used in surgeries for glaucoma and cataracts, among other conditions.
- Valeant is also in talks with Japan-based Takeda Pharmaceuticals to sell its stomach drug unit, Salix Pharmaceuticals, for an estimated $10 million.
- The drugmaker is sitting on a $30 billion debt pile, which includes $12 billion in bank loans.
More articles on supply chain:
The election and slowing drug sales: 6 things to know about the rocky week for big pharma
Pfizer ditches cholesterol drug development over lack of commercial potential
Valeant eyes potential $10B deal with Takedo to sell stomach drug business
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
